AQST
Aquestive TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Composite grade F from latest DB weights. Momentum 12.1 / Value 41.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
12
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.75
Why
Momentum12 · Δ7d +1.1
Value41 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
12
40% active weight
Current posture
7d trendSoftening
Δ7d
+1.1
Δ21d
-28.0
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 12.1 / Value 41.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$494.97M
Beta
1.65
Shares Out
125.47M
P/E (TTM) · Derived
-5.0
P/S (TTM)
17.51
P/FCF (TTM) · Derived
-10.15
Rev YoY
+65.7%
EPS YoY
-72.6%
Gross Margin
+63.5%
Op Margin
-128.6%
Net Debt
$10.28M
Current Ratio
4.10
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology